Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Astellas Pharma, Inc. and US biotech GO Therapeutics unveiled a research collaboration and licensing agreement on 1 June to apply advances in glycoproteomics toward the development of novel, targeted cancer immunotherapies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?